Last reviewed · How we verify
Pyoderma gangrenosum
Approved treatments
- Abrilada · AbbVie
Adalimumab-afzb binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors. - Humira · AbbVie
Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors. - CYLTEZO · BOEHRINGER INGELHEIM
- Lamprene · Novartis
- Humira · Sohag University
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Pyoderma gangrenosum patent landscape — cliff calendar, originator estates, attackable patents
- Pyoderma gangrenosum treatment landscape brief
- Pyoderma gangrenosum treatment updates RSS
Frequently asked questions about Pyoderma gangrenosum
What drugs treat Pyoderma gangrenosum?
Tracked treatments include Abrilada, Humira, CYLTEZO, Lamprene.
What is the treatment for Pyoderma gangrenosum?
Standard treatment for Pyoderma gangrenosum includes Abrilada, Humira, CYLTEZO, Lamprene. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Pyoderma gangrenosum patent cliff · Pyoderma gangrenosum CI report
- Treatment: Abrilada · AbbVie
- Treatment: Humira · AbbVie
- Treatment: CYLTEZO · BOEHRINGER INGELHEIM
- Treatment: Lamprene · Novartis
- Treatment: Humira · Sohag University
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing